SLN רווח נקי למניה ב-12 החודשים האחרונים Silence Therapeutics PLC

Silence Therapeutics is developing partnerships with pharmacology leaders to create RNA-based drugs targeting cardiovascular pathologies. The price action on the GURU.Markets rolling annual EPS chart, where -1.05 captures the value of this parameter, points toward a scalable gene-blocking algorithm platform that generates royalties. Robust patent barriers and years of R&D research ensure business stability, creating an insurmountable moat against competitors.
פילוחים אנליטיים ודוחות נתונים של חברת Silence Therapeutics Corp (SLN)

Silence Therapeutics operates in the high-risk RNA therapeutics sector, where financial results depend on regulatory approvals and partner payments. By analyzing the net income per share trend, an investor can observe a rolling annual total stripped of one-time non-cash revaluations, which allows for an assessment of the business's actual resilience and prevents the purchase of an overvalued asset amid volatile cash flows.